Danaher Co. (NYSE:DHR) Shares Acquired by Ledyard National Bank

Ledyard National Bank increased its position in Danaher Co. (NYSE:DHR) by 10.1% during the fourth quarter, Holdings Channel reports. The fund owned 6,229 shares of the conglomerate’s stock after purchasing an additional 571 shares during the quarter. Ledyard National Bank’s holdings in Danaher were worth $1,441,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of the company. Steele Capital Management Inc. acquired a new stake in shares of Danaher in the 4th quarter worth about $235,000. Naviter Wealth LLC increased its stake in Danaher by 19.6% during the 4th quarter. Naviter Wealth LLC now owns 7,305 shares of the conglomerate’s stock valued at $1,692,000 after buying an additional 1,199 shares during the period. Guyasuta Investment Advisors Inc. increased its stake in Danaher by 36.4% during the 4th quarter. Guyasuta Investment Advisors Inc. now owns 1,359 shares of the conglomerate’s stock valued at $314,000 after buying an additional 363 shares during the period. Choreo LLC increased its stake in Danaher by 174.8% during the 4th quarter. Choreo LLC now owns 3,284 shares of the conglomerate’s stock valued at $760,000 after buying an additional 2,089 shares during the period. Finally, Mather Group LLC. increased its stake in Danaher by 6.6% during the 4th quarter. Mather Group LLC. now owns 3,386 shares of the conglomerate’s stock valued at $783,000 after buying an additional 211 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Buying and Selling

In related news, Director Walter G. Lohr sold 3,289 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $251.15, for a total transaction of $826,032.35. Following the transaction, the director now owns 14,129 shares of the company’s stock, valued at $3,548,498.35. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, Director Walter G. Lohr sold 3,289 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $251.15, for a total transaction of $826,032.35. Following the transaction, the director now owns 14,129 shares of the company’s stock, valued at $3,548,498.35. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Georgeann Couchara sold 2,622 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the transaction, the senior vice president now directly owns 4,244 shares in the company, valued at approximately $1,029,891.48. The disclosure for this sale can be found here. Over the last three months, insiders sold 106,565 shares of company stock worth $26,641,364. 10.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and raised their target price for the company from $250.00 to $280.00 in a research note on Wednesday, April 17th. TD Cowen raised their price objective on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Raymond James raised their price objective on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. Barclays raised their price objective on shares of Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 24th. Finally, Robert W. Baird raised their price objective on shares of Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research report on Wednesday, April 24th. Six analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $269.64.

Danaher Stock Down 0.3 %

Shares of DHR stock traded down $0.79 during trading on Tuesday, hitting $246.03. 799,068 shares of the company were exchanged, compared to its average volume of 2,747,270. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. The firm has a market capitalization of $182.23 billion, a price-to-earnings ratio of 41.83, a P/E/G ratio of 3.80 and a beta of 0.83. The business’s 50-day simple moving average is $248.80 and its 200 day simple moving average is $231.53. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $259.00.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The firm’s quarterly revenue was down 2.6% compared to the same quarter last year. During the same period last year, the company posted $2.36 earnings per share. As a group, analysts forecast that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, April 26th. Investors of record on Thursday, March 28th were issued a dividend of $0.27 per share. This is a boost from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. The ex-dividend date of this dividend was Wednesday, March 27th. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.